Actelion Drug Meets Main Goal in Late-Stage Patient Study

June 16, 2014 7:10 AM

6 0

Actelion Ltd. (ATLN)’s experimental drug against a lung disease met the main goal of a late-stage study, potentially giving the drugmaker a pill that may garner annual sales of as much as 2 billion Swiss francs ($2.2 billion).

Actelion plans to apply for regulatory approval as soon as possible for selexipag, a treatment for pulmonary arterial hypertension, a deadly and incurable artery-narrowing disease, the Allschwil, Switzerland-based company said in a statement today. Barclays said it estimates peak sales at about 2 bi...

Read more

To category page